Switch theme
Sign up to access all valuation multiples
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its product pipeline includes ORMD-0801, ORMD-0801, and ORMD 0901.
2002
13
Last FY Revenue n/a
Last FY EBITDA -$14.9M
-$34.8M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Oramed Pharmaceuticals achieved revenue of n/a and an EBITDA of -$14.9M.
Oramed Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Oramed Pharmaceuticals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$14.9M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$13.7M | XXX | -$12.8M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$12.4M | XXX | -$19.1M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Oramed Pharmaceuticals's stock price is $2.
Oramed Pharmaceuticals has current market cap of $95.6M, and EV of -$34.8M.
See Oramed Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$34.8M | $95.6M | XXX | XXX | XXX | XXX | $-0.31 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Oramed Pharmaceuticals has market cap of $95.6M and EV of -$34.8M.
Oramed Pharmaceuticals's trades at -25.9x EV/Revenue multiple, and 2.3x EV/EBITDA.
Equity research analysts estimate Oramed Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Oramed Pharmaceuticals has a P/E ratio of -7.7x.
See valuation multiples for Oramed Pharmaceuticals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $95.6M | XXX | $95.6M | XXX | XXX | XXX |
| EV (current) | -$34.8M | XXX | -$34.8M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | -25.9x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 2.3x | XXX | XXX | XXX |
| EV/EBIT | 2.5x | XXX | 2.7x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -7.7x | XXX | -5.0x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 4.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialOramed Pharmaceuticals's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.0M for the same period.
Oramed Pharmaceuticals's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Oramed Pharmaceuticals's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Oramed Pharmaceuticals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Oramed Pharmaceuticals acquired XXX companies to date.
Last acquisition by Oramed Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Oramed Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Oramed Pharmaceuticals founded? | Oramed Pharmaceuticals was founded in 2002. |
| Where is Oramed Pharmaceuticals headquartered? | Oramed Pharmaceuticals is headquartered in United States of America. |
| How many employees does Oramed Pharmaceuticals have? | As of today, Oramed Pharmaceuticals has 13 employees. |
| Who is the CEO of Oramed Pharmaceuticals? | Oramed Pharmaceuticals's CEO is Mr. Nadav Kidron. |
| Is Oramed Pharmaceuticals publicy listed? | Yes, Oramed Pharmaceuticals is a public company listed on NAS. |
| What is the stock symbol of Oramed Pharmaceuticals? | Oramed Pharmaceuticals trades under ORMP ticker. |
| When did Oramed Pharmaceuticals go public? | Oramed Pharmaceuticals went public in 2007. |
| Who are competitors of Oramed Pharmaceuticals? | Similar companies to Oramed Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Oramed Pharmaceuticals? | Oramed Pharmaceuticals's current market cap is $95.6M |
| Is Oramed Pharmaceuticals profitable? | Yes, Oramed Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
